Low Screening Rates Despite a High Prevalence of Significant Liver Fibrosis in People with Diabetes from Primary and Secondary Care
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Low Screening Rates Despite a High Prevalence of Significant Liver Fibrosis in People with Diabetes from Primary and Secondary Care
Authors
Keywords
-
Journal
Journal of Clinical Medicine
Volume 10, Issue 24, Pages 5755
Publisher
MDPI AG
Online
2021-12-10
DOI
10.3390/jcm10245755
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults
- (2021) Jiaye Liu et al. Clinical Gastroenterology and Hepatology
- Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease
- (2021) Emily Brown et al. CLINICAL THERAPEUTICS
- EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update
- (2021) Annalisa Berzigotti et al. JOURNAL OF HEPATOLOGY
- MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease
- (2020) Mohammed Eslam et al. GASTROENTEROLOGY
- Non‐invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh type 2 diabetes study
- (2020) Sheila M. Grecian et al. LIVER INTERNATIONAL
- Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
- (2020) Romina Lomonaco et al. DIABETES CARE
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis
- (2019) Zobair M. Younossi et al. JOURNAL OF HEPATOLOGY
- The Risk of Incident Extrahepatic Cancers is higher in Nonalcoholic Fatty Liver Disease than Obesity - a Longitudinal Cohort Study
- (2019) Alina M. Allen et al. JOURNAL OF HEPATOLOGY
- Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study
- (2019) Francesco Baratta et al. Clinical Gastroenterology and Hepatology
- 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
- (2019) Gordon I. Smith et al. JOURNAL OF CLINICAL INVESTIGATION
- Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
- (2018) Jan W. Eriksson et al. DIABETOLOGIA
- The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe
- (2018) Tracey G. Simon et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial
- (2018) Naveed Sattar et al. DIABETOLOGIA
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
- (2017) Chris Estes et al. HEPATOLOGY
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis
- (2017) Parambir S. Dulai et al. HEPATOLOGY
- The Utility of Noninvasive Scores in Assessing the Prevalence of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Type 2 Diabetic Patients
- (2017) Amandeep Singh et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment
- (2017) Vincent Wai-Sun Wong et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
- (2016) Zobair M. Younossi et al. HEPATOLOGY
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- (2016) JOURNAL OF HEPATOLOGY
- Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial
- (2016) Jeffrey Cui et al. JOURNAL OF HEPATOLOGY
- Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE
- (2015) I. Doycheva et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies
- (2015) Siddharth Singh et al. Clinical Gastroenterology and Hepatology
- Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
- (2015) Eduardo Vilar-Gomez et al. GASTROENTEROLOGY
- Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study
- (2015) Edith M. Koehler et al. HEPATOLOGY
- Effect of Vildagliptin on Hepatic Steatosis
- (2015) Mavin Macauley et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management
- (2015) Stuart McPherson et al. JOURNAL OF HEPATOLOGY
- Type 2 diabetes mellitus
- (2015) Ralph A. DeFronzo et al. Nature Reviews Disease Primers
- Increased De Novo Lipogenesis Is a Distinct Characteristic of Individuals With Nonalcoholic Fatty Liver Disease
- (2013) Jennifer E. Lambert et al. GASTROENTEROLOGY
- The Enhanced Liver Fibrosis (ELF) score: Normal values, influence factors and proposed cut-off values
- (2013) Ralf Lichtinghagen et al. JOURNAL OF HEPATOLOGY
- Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: The Edinburgh type 2 diabetes study
- (2013) Joanne R. Morling et al. JOURNAL OF HEPATOLOGY
- Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
- (2013) Quentin M. Anstee et al. Nature Reviews Gastroenterology & Hepatology
- Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program
- (2012) M. J. Armstrong et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States
- (2012) Donghee Kim et al. HEPATOLOGY
- Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
- (2012) Daniel J. Cuthbertson et al. PLoS One
- Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis
- (2011) Ping Wang et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- The impact of liver fat vs visceral fat in determining categories of prediabetes
- (2010) K. Kantartzis et al. DIABETOLOGIA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started